In a capitalist market, the goal of a business is to sell a product to satisfy demand. In this context, a company's objective is to maximize profits. However, there are industries where the social good should take precedence over profits and the pharmaceutical Industry is an example of such an industry. Recently, an incident of arbitrary pricing by a pharmaceutical company has come to light. After years of research, the concerned company released a medicine for the treatment of a rare disease. It holds the patent for the medicine and has spent considerable R&D resources to produce the medicine. But the extraordinarily high price it has fixed for the medicine has not only dashed the hopes of patients suffering from the rare disease but has also shocked the conscience of the public at large. However, there are also some who are arguing that forcing the company to cap the price of the medicine will disincentivise pharmaceutical firms to conduct research and produce treatments for rare diseases in the future. In this context, answer the following: (a) What are the various issues in the above situation? (b) Do you think a price-cap solves the given problem by creating another one? (c) What are the long-term measures that can be taken to deal with issues arising in such cases? (Answer in 250 words)
Sudipa Dutta, AIR 41, 2025
India ranks 3rd in global pharmaceutical production by volume.
Stakeholder
Ethical dilemmas
1. Profits vs social ethics 2. Arbitrary pricing vs trusteeship 3. Business ethics vs public interest.
a) Issues involved in the above situation
1. Issue of pharmaceutical practices of arbitrary pricing -> of drugs and medicines 2. Principle of Sarvodaya not upheld -> by high cost of drugs 3. Disincentivization of R&D in medicine development due to putting a cap on drug prices 4. Scientific development vs Public upliftment -> deciding the issue of hegemony of companies or welfare of masses. 5. Issue of Environmental Social Governance (ESG) not upheld.
b) Price Cap solving one problem by creating another one
1. Disincentivizing research and development -> by hampering profit making endeavours of pharmaceutical companies. 2. Creation of poor quality drugs and medicines -> on account of lack of profit 3. Social integration threatened -> with rise in health issues on account of poor drug quality 4. Hampering foreign investment -> when appropriate profit is not realized. 5. Strikes by employees -> as lack of profit has a domino effect seen in wage cuts and layoffs. 6. Reduction in various business indicators -> due to worsening ease of doing business.
Long-term measures
1. Government funding for rare diseases drug development -> as there is less profit in developing drugs for this. 2. Engaging NGOs and civil society -> for taking up the issue of high price that can be realised by crowd funding. 3. Promote sustainable corporate governance. 4. Profit motive should be based on social upliftment -> realizing Corporate Social Responsibility. 5. Providing with government research and development facilities for high cost research. 6. Promoting ease of doing business.
Business management should involve doing Kushal Karma that is beneficial to all and not only for garnering wealth.